embolization
搜索文档
Penumbra raises 2025 revenue guidance to $1.375B–$1.38B as CAVT and embolization drive growth (NYSE:PEN)
Seeking Alpha· 2025-11-06 08:32
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...